Compare PRT & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRT | ALLR |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 26.1M |
| IPO Year | N/A | 2021 |
| Metric | PRT | ALLR |
|---|---|---|
| Price | $2.07 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 74.2K | ★ 223.2K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $0.77 |
| 52 Week High | $4.28 | $2.35 |
| Indicator | PRT | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 52.06 |
| Support Level | $1.82 | $1.53 |
| Resistance Level | $3.57 | $1.80 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 66.67 | 40.52 |
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.